- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06846671
Un estudio de BGB-16673 en comparación con la elección del investigador en los participantes con leucemia linfocítica crónica previamente expuesta a inhibidores de la tirosina quinasa (BTK) y la leucemia de células B/proteína de linfoma 2 (BCL2) (BCL2) (CaDAnCe-302)
Un estudio aleatorizado de fase 3 de fase 3 de BGB-16673 en comparación con la elección del investigador (idelalisib más rituximab o bendamustine más rituximab o venetoclax más retratamiento de rituximab) en pacientes con leucemia lymfocítica crónica previamente expuesta a BTK y BCL2 inhibidores de BCL2 y BCL2
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.
In this study, participants with relapsed/refractory (R/R) CLL who were previously exposed to a BTKi and a BCL2i will receive tacabrutideg or the investigator's choice of idelalisib plus rituximab (for CLL only) or bendamustine plus rituximab or venetoclax plus rituximab retreatment. The main purpose of this study is to compare the length of time that participants live without their CLL or SLL worsening between those participants who receive tacabrutideg versus the investigator's choice of treatment (idelalisib plus rituximab or bendamustine plus rituximab, or venetoclax plus rituximab).
Approximately 250 participants will be included in this study around the world. Participants will be randomly allocated to receive either tacabrutideg or the investigator's choice of treatment.
"Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website."
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Director
- Número de teléfono: 1.877.828.5568
- Correo electrónico: clinicaltrials@beonemed.com
Ubicaciones de estudio
-
-
-
Augsburg, Alemania, 86156
- Reclutamiento
- Universitatsklinikum Augsburg
-
Berlin, Alemania, 10715
- Reclutamiento
- Praxis Am Volkspark
-
Chemnitz, Alemania, 09116
- Reclutamiento
- Klinikum Chemnitz Ggmbh
-
Essen, Alemania, 45122
- Reclutamiento
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main, Alemania, 60389
- Reclutamiento
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau, Alemania, 79106
- Reclutamiento
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg, Alemania, 20251
- Reclutamiento
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg, Alemania, 69120
- Reclutamiento
- Universitatsklinikum Heidelberg
-
Homburg, Alemania, 66421
- Reclutamiento
- Universitatsklinikum Des Saarlandes
-
Koblenz, Alemania, 56068
- Reclutamiento
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig, Alemania, 04103
- Reclutamiento
- Universitaetsklinikum Leipzig Aor
-
Münster, Alemania, 48149
- Reclutamiento
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
-
Caba, Argentina, CP1114
- Reclutamiento
- FUNDALEU
-
Caba, Argentina, C1431
- Reclutamiento
- CEMIC
-
Caba, Argentina, 1425
- Reclutamiento
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires, Argentina, 1413
- Reclutamiento
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires, Argentina, 1426
- Reclutamiento
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán, Argentina, 4000
- Reclutamiento
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
New South Wales
-
Concord, New South Wales, Australia, NSW 2139
- Reclutamiento
- Concord Repatriation General Hospital
-
Gosford, New South Wales, Australia, NSW 2250
- Reclutamiento
- Gosford Hospital
-
Port Macquarie, New South Wales, Australia, NSW 2444
- Reclutamiento
- Port Macquarie Base Hospital
-
Randwick, New South Wales, Australia, NSW 2031
- Reclutamiento
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba, Queensland, Australia, QLD 4350
- Reclutamiento
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK, South Australia, Australia, SA 5042
- Reclutamiento
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australia, VIC 3004
- Reclutamiento
- The Alfred Hospital
-
-
Western Australia
-
West Perth, Western Australia, Australia, WA 6005
- Reclutamiento
- Perth Blood Institute
-
-
-
-
-
Belo Horizonte, Brasil, 30110-022
- Reclutamiento
- CETUS
-
Brasília, Brasil, 70200-730
- Reclutamiento
- Hospital Sirio Libanes Brasilia
-
Curitiba, Brasil, 81520-060
- Reclutamiento
- Hospital Erasto Gaertner
-
Florianópolis, Brasil, 88020-210
- Reclutamiento
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville, Brasil, 89201-260
- Reclutamiento
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói, Brasil, 24020-096
- Reclutamiento
- Complexo Hospitalar de Niteroi
-
Porto Alegre, Brasil, 90110-270
- Reclutamiento
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro, Brasil, 22250-040
- Reclutamiento
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro, Brasil, 22061-080
- Reclutamiento
- Hospital Sao Lucas Dasa Oncologia
-
Salvador, Brasil, 41253-190
- Reclutamiento
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brasil, 05652-900
- Reclutamiento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 04014-002
- Reclutamiento
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo, Brasil, 01401-004
- Reclutamiento
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória, Brasil, 29043-260
- Reclutamiento
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Reclutamiento
- Juravinski Cancer Centre
-
London, Ontario, Canadá, N6A 5W9
- Reclutamiento
- London Health Sciences Centre
-
Ottawa, Ontario, Canadá, K1H 8L6
- Reclutamiento
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canadá, J4V 2H1
- Reclutamiento
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal, Quebec, Canadá, QC H3t 1E2
- Reclutamiento
- Jewish General Hospital
-
SaintJerome, Quebec, Canadá, J7Z 5T3
- Reclutamiento
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
-
Brno, Chequia, 625 00
- Reclutamiento
- Fakultni Nemocnice Brno
-
Hradec Králové, Chequia, 500 03
- Reclutamiento
- Fakultni Nemocnice Hradec Kralove
-
Ostrava, Chequia, 708 00
- Reclutamiento
- Fakultni Nemocnice Ostrava
-
Prague, Chequia, 10000
- Reclutamiento
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
Busan Gwang'yeogsi
-
Seogu, Busan Gwang'yeogsi, Corea del Sur, 49201
- Reclutamiento
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu, Daegu Gwang'yeogsi, Corea del Sur, 41944
- Reclutamiento
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi, Gyeonggi-do, Corea del Sur, 10408
- Reclutamiento
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun, Jeonnam-Gwangju S.M. City, Corea del Sur, 58128
- Reclutamiento
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Corea del Sur, 06591
- Reclutamiento
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul, Seoul Teugbyeolsi, Corea del Sur, 03080
- Reclutamiento
- Seoul National University Hospital
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Reclutamiento
- St Bernards Medical Center
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-3075
- Reclutamiento
- UCLA Department of Medicine Hematologyoncology
-
San Diego, California, Estados Unidos, 92103-2106
- Reclutamiento
- Scripps Prebys Cancer Center
-
Whittier, California, Estados Unidos, 90602
- Reclutamiento
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012-5405
- Reclutamiento
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden, Colorado, Estados Unidos, 80401
- Reclutamiento
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33912
- Reclutamiento
- Florida Oncology and Hematology
-
Jacksonville, Florida, Estados Unidos, 32207-8432
- Reclutamiento
- Baptist Md Anderson Cancer Center
-
Weston, Florida, Estados Unidos, 33331-3609
- Reclutamiento
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322-1013
- Reclutamiento
- Emory University Winship Cancer Institute
-
Atlanta, Georgia, Estados Unidos, 30342
- Reclutamiento
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70808-4365
- Reclutamiento
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20817-7847
- Reclutamiento
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503-2560
- Reclutamiento
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455-0341
- Reclutamiento
- University of Minnesota
-
-
Missouri
-
Chesterfield, Missouri, Estados Unidos, 63017
- Reclutamiento
- St Lukes Center For Cancer Care
-
Springfield, Missouri, Estados Unidos, 65807-5288
- Reclutamiento
- Oncology Hematology Associates
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102-6746
- Reclutamiento
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130-2042
- Reclutamiento
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York, New York, Estados Unidos, 10065-6800
- Reclutamiento
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley, New York, Estados Unidos, 11967
- Reclutamiento
- New York Cancer and Blood Specialists
-
Westbury, New York, Estados Unidos, 11590-5119
- Reclutamiento
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106-1716
- Reclutamiento
- University Hospitals
-
Dayton, Ohio, Estados Unidos, 45415
- Reclutamiento
- Dayton Physician Network
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Reclutamiento
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- West Penn Hospital
-
York, Pennsylvania, Estados Unidos, 17403-5049
- Reclutamiento
- Cancer Care Associates of York
-
-
Texas
-
Temple, Texas, Estados Unidos, 76508-0001
- Reclutamiento
- Baylor Scott and White Health
-
Tyler, Texas, Estados Unidos, 75702-7522
- Reclutamiento
- Texas Oncology Tyler
-
-
-
-
-
Bari, Italia, 70124
- Reclutamiento
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence, Italia, 50134
- Reclutamiento
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italia, 20132
- Reclutamiento
- Ospedale San Raffaele
-
Milan, Italia, 20122
- Reclutamiento
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples, Italia, 80131
- Reclutamiento
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara, Italia, 28100
- Reclutamiento
- Aou Maggiore Della Carita
-
Pavia, Italia, 27100
- Reclutamiento
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia, Italia, 6129
- Reclutamiento
- Ospedale Santa Maria Della Misericordia
-
Roma, Italia, 00168
- Reclutamiento
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Kumamoto, Japón, 860-8556
- Reclutamiento
- Kumamoto University Hospital
-
Okayama, Japón, 701-1192
- Reclutamiento
- National Hospital Organization Okayama Medical Center
-
Osaka, Japón, 545-8586
- Reclutamiento
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 464-8681
- Reclutamiento
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba, Chiba, Japón, 260-8717
- Reclutamiento
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, Japón, 791-0280
- Reclutamiento
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japón, 730-8619
- Reclutamiento
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 064-0804
- Reclutamiento
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity, Hyōgo, Japón, 660-8550
- Reclutamiento
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japón, 890-8520
- Reclutamiento
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi, Kyoto, Japón, 602-8566
- Reclutamiento
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japón, 980-8574
- Reclutamiento
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, Japón, 951-8520
- Reclutamiento
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, Japón, 710-8602
- Reclutamiento
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata, Osaka, Japón, 573-1191
- Reclutamiento
- Kansai Medical University Hospital
-
Sakai, Osaka, Japón, 590-0197
- Reclutamiento
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi, Saitama, Japón, 350-8550
- Reclutamiento
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku, Tokyo, Japón, 113-8677
- Reclutamiento
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku, Tokyo, Japón, 141-0022
- Reclutamiento
- Ntt Medical Center Tokyo
-
-
-
-
-
Amsterdam, Países Bajos, 1081 HV
- Reclutamiento
- Amsterdam Umc Vu Mc
-
-
-
-
-
Brzozów, Polonia, 36-200
- Reclutamiento
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polonia, 40-519
- Reclutamiento
- Pratia Onkologia Katowice
-
Krakow, Polonia, 30-727
- Reclutamiento
- Pratia McM Krakow
-
Lodz, Polonia, 93-513
- Reclutamiento
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, Polonia, 20-090
- Reclutamiento
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polonia, 50-367
- Reclutamiento
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Aberdeen, Reino Unido, AB25 2ZN
- Reclutamiento
- Aberdeen Royal Infirmary
-
Birmingham, Reino Unido, B9 5SS
- Reclutamiento
- Birmingham Heartlands Hospital
-
Bournemouth, Reino Unido, BH7 7DW
- Reclutamiento
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London, Reino Unido, SW3 6JJ
- Reclutamiento
- Royal Marsden Hospital
-
London, Reino Unido, NW1 2PG
- Reclutamiento
- University College Hospital
-
Southampton, Reino Unido, SO16 6YD
- Reclutamiento
- Southampton General Hospital
-
-
-
-
-
Ankara, Turquía (Türkiye), 6500
- Reclutamiento
- Gazi University
-
Ankara, Turquía (Türkiye), 06200
- Reclutamiento
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova, Turquía (Türkiye), 35330
- Reclutamiento
- Dokuz Eylul University
-
Dokuma, Turquía (Türkiye), 07025
- Reclutamiento
- Antalya Memorial Hospital
-
Sakarya, Turquía (Türkiye), 54100
- Reclutamiento
- Sakarya Training and Research Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Adequate liver function
- Adequate blood clotting function
Exclusion Criteria:
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months
- Known central nervous system involvement
- Prior exposure to any BTK protein degraders
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
- Clinically significant cardiovascular disease
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
Otros nombres:
|
|
Comparador activo: Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Periodo de tiempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Periodo de tiempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
Periodo de tiempo: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
Periodo de tiempo: Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (Cri), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Periodo de tiempo: Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
Periodo de tiempo: Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
Periodo de tiempo: Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Periodo de tiempo: Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning Scales
Periodo de tiempo: Approximately 24 Months
|
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Periodo de tiempo: Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Study Director, BeOne Medicines
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Leucemia de células B
- Leucemia Linfoide
- Leucemia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Leucemia Linfocítica Crónica De Células B
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Benzimidazoles
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Ácidos, acíclico
- Ácidos carboxílicos
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Butiratos
- Anticuerpos, monoclonales, derivados de murino
- Clorhidrato de bendamustina
- Rituximab
- venetoclax
- idelalisib
Otros números de identificación del estudio
- BGB-16673-302
- 2024-518893-15-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Marco de tiempo para compartir IPD
See plan description
Criterios de acceso compartido de IPD
See plan description
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .